Stock listing
OTC:ZVSA ZyVersa Therapeutics, Inc. Stock
Follow ZyVersa Therapeutics, Inc. into a list and get an email when it puts out news.
Share price · OTC:ZVSA
$0.0001 USD 0.0000 (0.0%)
Close on Nov 20, 2026
- Day range
- $0.0001 – $0.0001 USDNov 20, 2026
- Volume
- 3,400 sharesNov 20, 2026
- Market cap
- $810 USDAt the close on Nov 20, 2026 · price × 8.10M shares outstanding
- 52-week range
- $0.0001 – $0.3000 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $672 USDMedian day 2,195 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · OTC:ZVSA · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 3,400 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 100 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 1,077 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 3,676 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 1,184 | |
| $0.0001 | -0.0009 | -90.0% | $0.0001 | $0.0001 | $0.0001 | 1,730 | |
| $0.0010 | 0.0000 | 0.0% | $0.0010 | $0.0010 | $0.0010 | 150 | |
| $0.0010 | 0.0000 | 0.0% | $0.0004 | $0.0010 | $0.0004 | 3,748 | |
| $0.0010 | 0.0000 | 0.0% | $0.0010 | $0.0010 | $0.0010 | 743 | |
| $0.0010 | 0.0000 | 0.0% | $0.0010 | $0.0010 | $0.0010 | 861 | |
| $0.0010 | +0.0008 | +400.0% | $0.0005 | $0.0010 | $0.0005 | 889 | |
| $0.0002 | -0.0478 | -99.6% | $0.0002 | $0.0002 | $0.0002 | 695 | |
| $0.0480 | +0.0035 | +7.9% | $0.0455 | $0.0500 | $0.0415 | 103,219 | |
| $0.0445 | -0.0350 | -44.0% | $0.0722 | $0.0722 | $0.0389 | 216,164 | |
| $0.0795 | -0.0004 | -0.5% | $0.0800 | $0.0800 | $0.0795 | 2,371 | |
| $0.0799 | +0.0001 | +0.1% | $0.0798 | $0.0799 | $0.0798 | 360 | |
| $0.0798 | +0.0003 | +0.4% | $0.0798 | $0.0798 | $0.0798 | 571 | |
| $0.0795 | -0.0028 | -3.4% | $0.0850 | $0.0850 | $0.0795 | 5,058 | |
| $0.0823 | +0.0028 | +3.5% | $0.0990 | $0.0990 | $0.0823 | 2,399 | |
| $0.0795 | -0.0005 | -0.6% | $0.0801 | $0.1018 | $0.0795 | 16,814 | |
| $0.0800 | 0.0000 | 0.0% | $0.0802 | $0.0802 | $0.0800 | 16,725 | |
| $0.0800 | -0.0222 | -21.7% | $0.0990 | $0.1020 | $0.0795 | 51,333 | |
| $0.1022 | -0.0048 | -4.5% | $0.1022 | $0.1022 | $0.1022 | 159 | |
| $0.1070 | +0.0040 | +3.9% | $0.0990 | $0.1070 | $0.0990 | 1,451 | |
| $0.1030 | +0.0040 | +4.0% | $0.0990 | $0.1149 | $0.0990 | 11,664 | |
| $0.0990 | -0.0051 | -4.9% | $0.0990 | $0.0990 | $0.0990 | 281 | |
| $0.1041 | +0.0041 | +4.1% | $0.0990 | $0.1041 | $0.0990 | 1,016 | |
| $0.1000 | +0.0010 | +1.0% | $0.1000 | $0.1000 | $0.1000 | 1,051 | |
| $0.0990 | -0.0144 | -12.7% | $0.0990 | $0.0990 | $0.0990 | 349 | |
| $0.1134 | +0.0144 | +14.5% | $0.1122 | $0.1134 | $0.1122 | 484 | |
| $0.0990 | 0.0000 | 0.0% | $0.0990 | $0.1149 | $0.0990 | 2,733 | |
| $0.0990 | 0.0000 | 0.0% | $0.1047 | $0.1047 | $0.0990 | 3,821 | |
| $0.0990 | -0.0080 | -7.5% | $0.0990 | $0.0990 | $0.0990 | 515 | |
| $0.1070 | +0.0080 | +8.1% | $0.1070 | $0.1070 | $0.1070 | 141 | |
| $0.0990 | -0.0010 | -1.0% | $0.0992 | $0.0992 | $0.0990 | 14,517 | |
| $0.1000 | +0.0010 | +1.0% | $0.0992 | $0.1149 | $0.0990 | 15,912 | |
| $0.0990 | -0.0002 | -0.2% | $0.0990 | $0.0990 | $0.0990 | 5,651 | |
| $0.0992 | -0.0038 | -3.7% | $0.0990 | $0.0992 | $0.0990 | 960 | |
| $0.1030 | +0.0038 | +3.8% | $0.0990 | $0.1030 | $0.0990 | 2,528 | |
| $0.0992 | 0.0000 | 0.0% | $0.0990 | $0.1071 | $0.0990 | 5,645 | |
| $0.0992 | +0.0002 | +0.2% | $0.0990 | $0.1039 | $0.0990 | 2,295 | |
| $0.0990 | 0.0000 | 0.0% | $0.0990 | $0.0990 | $0.0990 | 252 | |
| $0.0990 | -0.0060 | -5.7% | $0.1071 | $0.1140 | $0.0990 | 8,206 | |
| $0.1050 | +0.0060 | +6.1% | $0.1090 | $0.1090 | $0.1050 | 5,213 | |
| $0.0990 | 0.0000 | 0.0% | $0.1155 | $0.1155 | $0.0990 | 2,080 | |
| $0.0990 | -0.0005 | -0.5% | $0.1160 | $0.1160 | $0.0990 | 12,560 | |
| $0.0995 | 0.0000 | 0.0% | $0.1100 | $0.1100 | $0.0995 | 1,261 | |
| $0.0995 | -0.0037 | -3.6% | $0.1036 | $0.1036 | $0.0995 | 2,095 | |
| $0.1032 | -0.0068 | -6.2% | $0.0990 | $0.1075 | $0.0990 | 2,610 | |
| $0.1100 | +0.0110 | +11.1% | $0.1100 | $0.1170 | $0.0990 | 7,027 |
Splits
2 splits since 2023 · OTC:ZVSA · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-10 | Consolidation | |
| 1-for-35 | Consolidation |
- Ticker
- OTC:ZVSA
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- OTC
- Currency
- USD
What changed lately
Latest deck · 2026
Investor Presentation (2026)
Investor deck · 18 slides
ZyVersa Therapeutics, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- Decks
- 2 decks · latest 2026
Valuation
Statements: 4 quarters to Mar 31, 2026 · price Nov 20, 2026
- Enterprise value
- $1.20B USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- No depreciation figure on 6ix yet
- Price/book
- Negative equity
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- Negative equity
- Beta vs S&P 500
- -0.56
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| ZyVersa Therapeutics, Inc. · OTC:ZVSA | US$810 | US$1.20B | n/a | n/a | n/a | n/a | n/a | n/a | -0.56 |
| Vaxil Bio Ltd. · TSXV:VXL | US$319,477 | −US$4,071 | 1.2× | n/a | n/a | 0.4× | n/a | 0.0× | -0.16 |
| Chimeric Therapeutics Limited · ASX:CHM | US$292,816 | −US$220,193 | n/a | −0.1× | n/a | 0.2× | −262.8% | 2.5× | n/a |
| CERo Therapeutics Holdings, Inc. · OTC:CERO | US$265,035 | −US$190,890 | n/a | n/a | n/a | n/a | n/a | n/a | 1.47 |
| CDT Equity Inc. · NASDAQ:CDT | US$234,109 | −US$1.49M | n/a | n/a | n/a | 0.0× | n/a | 0.0× | 1.14 |
| GlucoTrack, Inc. · NASDAQ:GCTK | US$217,049 | −US$887,951 | n/a | n/a | n/a | n/a | n/a | n/a | 1.73 |
| Regen BioPharma, Inc. · OTC:RGBP | US$167,528 | US$167,289 | n/a | 0.7× | n/a | n/a | −501.4% | n/a | 1.20 |
| CNBX Pharmaceuticals Inc. · OTC:CNBX | US$160,577 | US$151,090 | n/a | n/a | n/a | n/a | n/a | n/a | 1.78 |
| Fifty 1 Labs Inc. · OTC:FITY | US$118,532 | US$282,021 | n/a | 6,000× | n/a | n/a | n/a | n/a | -1.17 |
| GB Sciences, Inc. · OTC:GBLX | US$81,414 | US$2.07M | n/a | n/a | n/a | n/a | n/a | n/a | -0.46 |
| Lyra Therapeutics, Inc. · OTC:LYRA | US$53,246 | US$14.42M | n/a | 36.2× | n/a | n/a | n/a | n/a | 0.67 |
| Median of the others | US$192,289 | US$73,510 | 1.2× | 18.5× | 0.2× | −382.1% | 0.0× | 1.14 |
Team and board
Officers
| Officer | Role |
|---|---|
| James Sapirstein | Chairman and CEO – 8 Prime Biosciences |
| Stephen C. Glover | Co-founder, Chairman, CEO, and President |
| Peter Wolfe | Chief Financial Officer |
| Karen Cashmere | Chief Commercial Officer |
Board
| Director | Role |
|---|---|
| James Sapirstein | Chairman and CEO – 8 Prime Biosciences |
| Stephen C. Glover | Co-founder, Chairman, CEO, and President |
| Gregory G. Freitag | Principal of FreiMc |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q1 2026 | May 19, 2026 | −8.0% |
| Q3 2025 | Nov 19, 2025 | 0.0% |
| Q2 2025 | Aug 13, 2025 | +7.3% |
| Q1 2025 | May 12, 2025 | −1.8% |
| Q4 2024 | Mar 27, 2025 | −17.8% |
| Q3 2024 | Nov 14, 2024 · Before open | −9.6% |
| Q2 2024 | Aug 9, 2024 · After close | −5.6% |
| Q1 2024 | May 15, 2024 · Before open | −6.6% |
| Q4 2023 | Mar 25, 2024 · Before open | −2.0% |
| Q3 2023 | Nov 14, 2023 · After close | −1.1% |
All 16 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q2 2023 | Aug 21, 2023 · After close | −6.5% |
| Q1 2023 | Apr 12, 2023 | +4.7% |
| Q3 2022 | Nov 14, 2022 | +0.4% |
| Q2 2022 | Aug 15, 2022 | 0.0% |
| Q1 2022 | Apr 15, 2022 | |
| Q3 2021 | Dec 22, 2021 |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (2026) | Investor deck | 18 slides | 2026 |
| SPAC Merger (July 2022) | SPAC merger | 51 slides | Jul 22, 2022 |
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of revenue | 6.93K | 10.4K | 10.4K | 10.4K | 10.4K | |
| Gross profit | -6.93K | -10.4K | -10.4K | -10.4K | -10.4K | |
| Research and development | 1.11M | 1.78M | 3.21M | 5.41M | 2.12M | 6.47M |
| Selling, general and administrative | 5.73B | 7.36B | 11.2B | 7.61M | 5.58M | 5.36M |
| Operating income | -25.5M | -9.14M | -107.8M | -13.8M | -7.70M | -11.8M |
| Depreciation and amortization | 0 | 6.93K | 10.4K | 9.87K | 10.4K | 10.4K |
| EBITDA | -25.5M | -9.13M | -107.7M | -13.8M | -7.69M | -11.8M |
| Interest expense | 513.2K | 269.9K | 457.0K | 427.5K | 821.4K | 516.5K |
| Income before tax | -25.8M | -9.41M | -107.8M | -14.9M | -8.08M | -12.7M |
| Income tax | -851.7K | 6.75K | -9.46M | -745.0K | 821.4K | 516.5K |
| Net income | -25.0M | -9.41M | -98.3M | -14.0M | -8.08M | -12.7M |
| Earnings per share, basic | -4.18 | -8.48 | -1,089.70 | -541.38 | -173.66 | -272.45 |
| Earnings per share, diluted | -4.18 | -8.48 | -1,089.70 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Cash and equivalents | 101.8K | 1.53M | 3.14M | 5.90M | 328.6K | 174.7K |
| Short-term investments | 1.53B | |||||
| Current assets | 463.5K | 1.72M | 3.35M | 6.36M | 811.8K | 339.1K |
| Property, plant and equipment | 6.93K | 115.7K | 27.7K | 38.1K | ||
| Goodwill | 0 | 11.9M | 0 | |||
| Total assets | 463.5K | 20.6M | 22.1M | 118.5M | 1.13M | 685.6K |
| Accounts payable | 10.1M | 9.34M | 8.43M | 6.03M | 2.00M | 2.31M |
| Current liabilities | 12.9M | 11.2M | 10.2M | 8.19M | 13.6M | 7.56M |
| Long-term debt | 1.69M | |||||
| Total debt | 8.66K | 108.8K | 9.15M | 3.82M | ||
| Total liabilities | 12.9M | 12.1M | 11.0M | 18.5M | 13.6M | 9.24M |
| Shareholders' equity | -12.4M | 8.52M | 11.1M | 100.0M | -12.5M | -8.56M |
| Shares outstanding | 8.10M | 2.51M | 402.2K | 25.9K | 46.6K | 46.6K |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Cash from operations | -5.11M | -7.52M | -8.72M | -4.89M | -5.08M | -5.11M |
| Capital spending | 0 | -3 | -1 | 0 | 0 | 0 |
| Free cash flow | -5.11M | -7.56M | -8.72M | -1.49M | -5.08M | -5.11M |
| Cash from financing | 3.69M | 5.91M | 5.96M | 1.87M | 5.23M | 4.56M |
| Share buybacks | 0 | -10.7M | 0 | |||
| Change in cash | -1.43M | -1.61M | -2.76M | 5.57M | 153.9K | -549.8K |
Cap table
Built by 6ix from ZyVersa Therapeutics, Inc.’s releases
- Common shares
- 8,095,921
- Fully diluted
- 8,095,921
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 8,095,921 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 8,095,921 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| James Sapirstein Other companies: INmune Bio Inc. (Director · Since at least Sep 8, 2026); Cocrystal Pharma, Inc. (Chief Executive Officer · Since at least Jun 3, 2026); Onconetix, Inc. (Director · Feb 23, 2022 – Sep 26, 2024 · Past); Blue Water Acquisition Corp (Director · Dec 15, 2020 – Dec 15, 2020 · Past); Marizyme, Inc. (Interim CEO, Director · Sep 10, 2020 – Mar 5, 2021 · Past); GridAI Technologies Corp. (Chairman and CEO, Director · Oct 8, 2019 – Jul 2, 2024 · Past); Lunai Bioworks Inc. (Director · Mar 6, 2018 – Jun 25, 2024 · Past); Hepion Pharmaceuticals, Inc. (Chief Executive Officer, Director · Jan 3, 2018 – Jan 3, 2018 · Past); RespireRx Pharmaceuticals Inc (Director · Dec 9, 2017 – Dec 9, 2017 · Past) | Director · Since at least Jan 5, 2023 |
| Stephen C. Glover Other companies: Oncolytics Biotech Inc. (Director · Since at least Jun 1, 2026); PDS Biotechnology Corporation (Director · Since at least Apr 2, 2019); Ambrx Biopharma Inc. (Director · May 18, 2023 – Mar 7, 2024 · Past); Insmed Incorporated (President Follow-on Biologics · Jun 22, 2007 – Mar 31, 2009 · Past) | Co-founder, Chairman, CEO, and President · Since at least Dec 12, 2022 |
| Gregory G. Freitag Other companies: PDS Biotechnology Corporation (Director · Since at least Mar 15, 2019); Pressure BioSciences, Inc. (Director · Jul 27, 2010 – Apr 5, 2012 · Past); Axogen, Inc. (Director · Jun 1, 2010 – Jun 4, 2024 · Past) | Principal of FreiMc · Since at least Jan 5, 2023 |
| Daniel O’Connor Other companies: DiaMedica Therapeutics Inc. (Director · Since at least Feb 20, 2025); Ambrx Biopharma Inc. (President and CEO, Director · Jan 1, 2023 – Mar 7, 2024 · Past) | Director · Dec 20, 2021 – Dec 12, 2022 · Past |
| David Briones Other companies: Hoth Therapeutics, Inc. (Chief Financial Officer · Since at least Mar 5, 2019); Unique Logistics International Inc (Director · Sep 6, 2022 – May 14, 2025 · Past) | Chief Financial Officer, Director · Dec 20, 2021 – Jan 6, 2022 · Past |
| Robert G Finizio Other companies: TherapeuticsMD, Inc. (CEO, Director · Feb 28, 2019 – Jul 1, 2021 · Past) | Director · Since at least Dec 12, 2022 |
| Gregory Skalicky | Director · Dec 20, 2021 – Jan 6, 2022 · Past |
| Karen Cashmere | Chief Commercial Officer · Since at least Dec 12, 2022 |
| Min-Chul Park | Director · Since at least Jul 11, 2025 |
| Nicholas A LaBella Jr | Chief Scientific Officer · Dec 12, 2022 – Dec 12, 2022 · Past |
All 13 people
| Person | Seat |
|---|---|
| Pablo A Guzman | Chief Medical Officer · Since at least Jul 11, 2025 |
| Peter Wolfe | Chief Financial Officer · Since at least Jul 18, 2024 |
| Raj Mehra | Director · Dec 20, 2021 – Jan 6, 2022 · Past |
Log in to ask 6ix AI your own questions about ZyVersa Therapeutics, Inc.